Cognito Therapeutics is one of the most advanced companies in the gamma entrainment space, with clinical evidence suggesting disease-modifying effects in Alzheimer’s. Its Series C+ funding and clinical progress position it as a leading non-invasive therapeutic contender, though long-term efficacy remains under investigation.